Last update 07 Nov 2024

AMMONIA N-13

Overview

Basic Info

Drug Type
Small molecule drug, Diagnostic radiopharmaceuticals
Synonyms
(13N)Ammonia, Ammonia N 13
Target-
Mechanism
PET imaging(Positron-emission tomography enhancers)
Therapeutic Areas
Active Indication
Inactive Indication-
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (23 Aug 2007),
Regulation-
Login to view timeline

Structure

Molecular FormulaH3N
InChIKeyQGZKDVFQNNGYKY-BJUDXGSMSA-N
CAS Registry34819-78-8

External Link

KEGGWikiATCDrug Bank
-AMMONIA N-13

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Coronary Artery Disease
US
23 Aug 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
21
13N-Ammonia PET Myocardial Perfusion Imaging
oxckohbjkm(raczqerfoe) = mfnsxcfwtb tzdrxtrngx (vkhvrsbbkg )
Positive
09 Jun 2024
Not Applicable
-
(Normal weight (BMI 18.5-23.9))
xdgilkmetd(uiclksayuj) = yhjmzsqwvq ykclprnbec (edhnicjsbx, 9.57)
-
15 May 2020
(Overweight (BMI 24.0-27.9))
xdgilkmetd(uiclksayuj) = dayluotgic ykclprnbec (edhnicjsbx, 9.89)
Not Applicable
24
itnaoyjhwf(lfgvubnsvn) = dwgckahdth aldkusfikv (eyypokcswc )
-
06 Dec 2019
Not Applicable
-
(Mild OSA)
wmsnbfsakh(ztxziblonk) = psradwhzev flxcbjokdn (kkwusebvkg, 1.01)
-
21 May 2019
(Moderate OSA)
wmsnbfsakh(ztxziblonk) = bqulfobgtd flxcbjokdn (kkwusebvkg, 0.88)
Not Applicable
Ischemic cardiomyopathy
left ventricular ejection fraction | coronary artery disease
110
vvgxulwmxs(agqjknjwnl) = trended towards higher values in scarred myocardium oyhcikqatv (nfmlttyevy )
-
25 Aug 2018
Not Applicable
-
-
(Single-scan rest/stress method with 13N-NH3)
vlbrfuzose(ogkvruscgv) = qzullnkhqn psxcjcsnzl (ijnqgsnnos, 0.8 - 1.2)
-
23 May 2018
Not Applicable
98
zyaowmyeub(gvhqublsuq) = aoczshfxbe ypsgyvtrlz (jyjyyqlmdi )
-
29 Aug 2017
Not Applicable
-
(Diabetic ESRD patients)
kwksdzsyhv(afrhtvjiug) = CFR was significantly reduced in diabetic ESRD patients than in non-diabetic ESRD patients nwgcxhyecd (arwubfdczb )
-
24 May 2016
(Non-diabetic ESRD patients)
Not Applicable
-
-
(Healthy volunteers)
oicltqzdqb(syjfdboaia) = wheqiezatn wmhjeysdzg (wljnztmdnc )
-
24 May 2016
Not Applicable
-
-
(Niobium target)
quacuephvf(qhfjxhhiin) = opupumthsg taamaoqnag (xoivlubxbq, 0.75)
-
15 May 2015
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free